Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

News

24 stocks for 2030

Susan Dziubinski  |  01 Oct 2020Text size  Decrease  Increase  |  
Email to Friend

Stock investing in 2020 has been tumultuous, to say the least. The market hit new highs early in the year, was derailed by the COVID-19 worries, and then rebounded with head-spinning speed.

The persistence of the coronavirus pandemic, economic uncertainty, and an upcoming U.S. election will likely keep stock investors on their toes for the foreseeable future.

What’s the prescription for successful stock-picking during times of turmoil? At Morningstar, we think the keys are focusing on the fundamentals and investing for the long term.

During the 2020 Morningstar Investment Conference, a team of Morningstar’s senior equity analysts applied our fundamentals-based approach to a handful of investment themes we expect to dominate during the next decade—and shared a few of their best ideas in those themes.

Here’s a recap.

Theme 1: Cannabis

Cannabis stocks have been on a rollercoaster the past few years, acknowledges sector director Kris Inton. We nevertheless expect to see a good deal of change in cannabis consumption in the coming decade, which will drive growth. Right now, the legal U.S. market is estimated at more than $US10 billion; by 2030, we forecast that figure to balloon to more than $US80 billion, he reports.

Where will that growth come from? Additional states will likely legalize tetrahydrocannabinol, or THC, cannabis—and the pandemic may only accelerate that, as states look for new tax dollars to plug budget gaps, says Inton. We also think users from the black market will migrate to the regulated, legal market, and that some non-users may become consumers upon legality.

“The legal market is set for massive growth benefiting all cannabis producers,” concludes Inton.

Several of the cannabis producers we cover are undervalued today, although they carry no moat and an uncertainty rating of Very High or Extreme.

(The data for the stocks listed is as of 1 October 2020.)

Theme 2: 5G

“We view 5G as more evolutionary than revolutionary for wireless carriers,” asserts sector director Mike Hodel. We expect wireless carriers to continue to invest in their networks to keep up with customer demand and improve service.

We think that the firms that stand to benefit most from 5G are those that can leverage the technology to drive innovation, such as application developers or media firms. It’s tough to identify these companies in advance, admits Hodel, because so many will likely come in the form of start-ups.

That being said, companies that facilitate 5G-related services stand to benefit, too—including semiconductor firms like Skyworks, Qualcomm, and Qorvo, and equipment vendors such as Nokia. Dish Network might be of interest as a more speculative play, says Hodel, as it plans to build out a new wireless network. And for those seeking a pick among mainstream carriers, we like Verizon—but we’d like it more at a larger margin of safety.

Theme 3: Electric vehicles

We forecast that one in five vehicles sold globally in 2030 will be powered by electricity, reports senior analyst Seth Goldstein. Electric vehicle, or EV, adoption will increase once EVs reach cost and functional parity with internal combustion engine, or ICE, vehicles, which we expect to happen in 2025, he maintains.

What will that entail? On the cost front, we expect EVs to become cheaper than ICEs on a total cost of ownership basis by 2025, which includes purchase price, cost of refuelling (gas versus electricity), and maintenance. Indeed, we think EVs will be less costly by that time frame without subsidies, owing to cheaper batteries and greater manufacturing scale, says Goldstein. When it comes to functionality, we assume the median EV range on a single charge will exceed 300 miles, thanks to larger and more-efficient batteries. We see charge times falling, too, as chargers become more powerful, and the number of charging stations multiplying, he concludes.

We’re finding investment opportunities throughout the supply chain, including lithium producers, auto suppliers, and automakers. All the names below carry a narrow moat rating, except GM.

Theme 4: Renewable energy

Renewable energy has the chance to transform the energy landscape, eventually taking the place of fossil fuels, says strategist Travis Miller. While we don’t expect renewables to completely upend fossil fuels in the next decade, we are projecting renewables to make up 22 per cent of electricity generation by 2030, up from 7 per cent to 8 per cent today, he notes.

We expect a combination of corporate purchasing and state-level policies that promote renewable energy to drive growth. We think wind growth estimates are overstated and that solar will be the key disruptor.

Investors can gain exposure to renewable energy one of three ways—by investing directly in renewable energy manufacturers (such as First Solar), by picking up companies that invest in the infrastructure to support renewal energy (Edison International), or by buying companies that do both (NextEra Energy).

Theme 5: Big pharma/biotech

Several paradigm shifts are occurring that will allow Big Pharma and biotech to maintain their economic moats during the next decade, asserts strategist Karen Andersen. These companies have shifted their R&D focus away from primary care and toward niche diseases where drugmakers can maintain strong pricing for unmet demand, she says. Further, advances in immune-oncology, cell therapy, and gene therapy may transform cancer and rare-disease treatment. And thanks to the FDA’s willingness to rapidly approve innovative new drugs, drug development time is shrinking, she observes.

Nevertheless, pricing and policy remain headwinds for drugmakers. No matter who wins the White House in November, we expect some policy change, says Andersen—but we think any change will result in no more than a manageable 2 per cent hit to industry sales. Further, we expect fewer cases going forward of new drugs being priced well above cost-effectiveness guidelines.

Overall, though, ongoing innovation in pharma and biotech should more than offset patent losses and policy headwinds.

Morningstar's Global Best Ideas list is out now. Morningstar Premium subscribers can view the list here.

is director of content for Morningstar.com.

© 2020 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written consent of Morningstar. Any general advice or 'class service' have been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), or its Authorised Representatives, and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/s/fsg.pdf. Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Past performance does not necessarily indicate a financial product's future performance. To obtain advice tailored to your situation, contact a licensed financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782. The article is current as at date of publication.

Email To Friend